Yinan Lin advises life sciences companies on intellectual property strategy and transactions, with a particular focus on complex IP structuring, portfolio management, and strategic agreements. She works with pharmaceutical and biotechnology clients across the full innovation lifecycle—from early-stage research through clinical development, manufacturing, and commercialization—drawing on scientific fluency, patent expertise, and transactional insight.
With advanced training in chemistry and biomedical sciences, Yinan brings a thoughtful approach to protecting innovation in the life sciences. She has developed and implemented IP strategies for a range of therapeutic programs, including small molecules, biologics, and gene therapies. Her deal experience includes IP licensing and asset acquisitions, license terminations and program divestitures, mergers and business acquisitions, R&D collaborations, supply chain and distribution agreements, and other commercial agreements supporting business operations, financing, partnering, monetization, and broader strategic goals.